201 related articles for article (PubMed ID: 23955093)
1. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.
Atanackovic D; Reinhard H; Meyer S; Spöck S; Grob T; Luetkens T; Yousef S; Cao Y; Hildebrandt Y; Templin J; Bartels K; Lajmi N; Stoiber H; Kröger N; Atz J; Seimetz D; Izbicki JR; Bokemeyer C
Hum Vaccin Immunother; 2013 Dec; 9(12):2533-42. PubMed ID: 23955093
[TBL] [Abstract][Full Text] [Related]
2. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.
Goéré D; Gras-Chaput N; Aupérin A; Flament C; Mariette C; Glehen O; Zitvogel L; Elias D
BMC Cancer; 2014 Mar; 14():148. PubMed ID: 24589307
[TBL] [Abstract][Full Text] [Related]
3. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
[TBL] [Abstract][Full Text] [Related]
4. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
[TBL] [Abstract][Full Text] [Related]
5. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D; Lindhofer H; Bokemeyer C
Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
[TBL] [Abstract][Full Text] [Related]
6. Catumaxomab: a bispecific trifunctional antibody.
Sebastian M; Kuemmel A; Schmidt M; Schmittel A
Drugs Today (Barc); 2009 Aug; 45(8):589-97. PubMed ID: 19927225
[TBL] [Abstract][Full Text] [Related]
7. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.
Dettmar K; Seitz-Merwald I; Lindemann C; Schroeder P; Seimetz D; Atz J
Clin Transl Oncol; 2012 May; 14(5):376-81. PubMed ID: 22551544
[TBL] [Abstract][Full Text] [Related]
8. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
Ott MG; Marmé F; Moldenhauer G; Lindhofer H; Hennig M; Spannagl R; Essing MM; Linke R; Seimetz D
Int J Cancer; 2012 May; 130(9):2195-203. PubMed ID: 21702044
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
Sebastian M; Kiewe P; Schuette W; Brust D; Peschel C; Schneller F; Rühle KH; Nilius G; Ewert R; Lodziewski S; Passlick B; Sienel W; Wiewrodt R; Jäger M; Lindhofer H; Friccius-Quecke H; Schmittel A
J Immunother; 2009; 32(2):195-202. PubMed ID: 19238019
[TBL] [Abstract][Full Text] [Related]
10. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
Ruf P; Bauer HW; Schoberth A; Kellermann C; Lindhofer H
Cancer Immunol Immunother; 2021 Sep; 70(9):2727-2735. PubMed ID: 33837852
[TBL] [Abstract][Full Text] [Related]
11. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
12. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Knödler M; Körfer J; Kunzmann V; Trojan J; Daum S; Schenk M; Kullmann F; Schroll S; Behringer D; Stahl M; Al-Batran SE; Hacker U; Ibach S; Lindhofer H; Lordick F
Br J Cancer; 2018 Aug; 119(3):296-302. PubMed ID: 29988111
[TBL] [Abstract][Full Text] [Related]
13. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).
Seimetz D
J Cancer; 2011; 2():309-16. PubMed ID: 21716847
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of catumaxomab in gastric cancer.
Lordick F; Ott K; Weitz J; Jäger D
Expert Opin Biol Ther; 2008 Sep; 8(9):1407-15. PubMed ID: 18694358
[TBL] [Abstract][Full Text] [Related]
15. Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.
Petrelli F; Borgonovo K; Lonati V; Elia S; Barni S
Target Oncol; 2013 Dec; 8(4):291-4. PubMed ID: 23197249
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.
Hirschhaeuser F; Walenta S; Mueller-Klieser W
Cancer Immunol Immunother; 2010 Nov; 59(11):1675-84. PubMed ID: 20652245
[TBL] [Abstract][Full Text] [Related]
17. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
[TBL] [Abstract][Full Text] [Related]
19. Review of catumaxomab in the treatment of malignant ascites.
Sebastian M
Cancer Manag Res; 2010 Nov; 2():283-6. PubMed ID: 21188120
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer.
Bokemeyer C; Stein A; Ridwelski K; Atanackovic D; Arnold D; Wöll E; Ulrich A; Fischer R; Krüger C; Schuhmacher C
Gastric Cancer; 2015 Oct; 18(4):833-42. PubMed ID: 25214034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
